Position in SLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2026
1 quarter on record
Derivatives in SLS
reported options exposure · as of Jun 30, 2026CallValue
$0
CallShares
0
PutValue
$6,642,000
PutShares
450,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026LMR Partners LLP holds $188,560,243 across 75 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
134,214 | $40,402,439 | |
| 2 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
223,995 | $21,835,032 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,306 | $13,908,683 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
347,106 | $10,850,533 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
5,112,098 | $8,521,240 | |
| 6 | ARGX |
Argenx SE
|
8,200 | $7,607,714 | |
| 7 | DFTX |
Definium Therapeutics, Inc.
|
150,200 | $7,065,408 | |
| 8 | NKTR |
Nektar Therapeutics
|
100,000 | $6,981,000 |
All Filings in SLS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,642,000 | 450,000 | Put | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||